TNDM Relative Valuation
TNDM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TNDM is overvalued; if below, it's undervalued.
Historical Valuation
Tandem Diabetes Care Inc (TNDM) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 41.53. The fair price of Tandem Diabetes Care Inc (TNDM) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：19.93
Fair
-20.66
PE
1Y
3Y
5Y
Trailing
Forward
28.96
EV/EBITDA
Tandem Diabetes Care Inc. (TNDM) has a current EV/EBITDA of 28.96. The 5-year average EV/EBITDA is 146.10. The thresholds are as follows: Strongly Undervalued below -315.81, Undervalued between -315.81 and -84.85, Fairly Valued between 377.06 and -84.85, Overvalued between 377.06 and 608.01, and Strongly Overvalued above 608.01. The current Forward EV/EBITDA of 28.96 falls within the Historic Trend Line -Fairly Valued range.
-21.57
EV/EBIT
Tandem Diabetes Care Inc. (TNDM) has a current EV/EBIT of -21.57. The 5-year average EV/EBIT is 49.27. The thresholds are as follows: Strongly Undervalued below -217.14, Undervalued between -217.14 and -83.93, Fairly Valued between 182.47 and -83.93, Overvalued between 182.47 and 315.68, and Strongly Overvalued above 315.68. The current Forward EV/EBIT of -21.57 falls within the Historic Trend Line -Fairly Valued range.
1.26
PS
Tandem Diabetes Care Inc. (TNDM) has a current PS of 1.26. The 5-year average PS is 4.39. The thresholds are as follows: Strongly Undervalued below -2.17, Undervalued between -2.17 and 1.11, Fairly Valued between 7.67 and 1.11, Overvalued between 7.67 and 10.95, and Strongly Overvalued above 10.95. The current Forward PS of 1.26 falls within the Historic Trend Line -Fairly Valued range.
9.58
P/OCF
Tandem Diabetes Care Inc. (TNDM) has a current P/OCF of 9.58. The 5-year average P/OCF is 66.34. The thresholds are as follows: Strongly Undervalued below -85.92, Undervalued between -85.92 and -9.79, Fairly Valued between 142.48 and -9.79, Overvalued between 142.48 and 218.61, and Strongly Overvalued above 218.61. The current Forward P/OCF of 9.58 falls within the Historic Trend Line -Fairly Valued range.
11.85
P/FCF
Tandem Diabetes Care Inc. (TNDM) has a current P/FCF of 11.85. The 5-year average P/FCF is -40.94. The thresholds are as follows: Strongly Undervalued below -482.19, Undervalued between -482.19 and -261.56, Fairly Valued between 179.69 and -261.56, Overvalued between 179.69 and 400.32, and Strongly Overvalued above 400.32. The current Forward P/FCF of 11.85 falls within the Historic Trend Line -Fairly Valued range.
Tandem Diabetes Care Inc (TNDM) has a current Price-to-Book (P/B) ratio of 10.16. Compared to its 3-year average P/B ratio of 7.51 , the current P/B ratio is approximately 35.29% higher. Relative to its 5-year average P/B ratio of 10.66, the current P/B ratio is about -4.73% higher. Tandem Diabetes Care Inc (TNDM) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -1.34%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -0.38% , the current FCF yield is about -100.00% lower.
10.56
P/B
Median3y
7.51
Median5y
10.66
-1.86
FCF Yield
Median3y
-1.34
Median5y
-0.38
Competitors Valuation Multiple
The average P/S ratio for TNDM's competitors is , providing a benchmark for relative valuation. Tandem Diabetes Care Inc Corp (TNDM) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 2.17%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of TNDM decreased by 42.50% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 243.97M to 249.25M.
The secondary factor is the Margin Expansion, contributed -10.91%to the performance.
Overall, the performance of TNDM in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Tandem Diabetes Care Inc (TNDM) currently overvalued or undervalued?
What is Tandem Diabetes Care Inc (TNDM) fair value?
How does TNDM's valuation metrics compare to the industry average?
What is the current P/B ratio for Tandem Diabetes Care Inc (TNDM) as of Dec 05 2025?
What is the current FCF Yield for Tandem Diabetes Care Inc (TNDM) as of Dec 05 2025?
What is the current Forward P/E ratio for Tandem Diabetes Care Inc (TNDM) as of Dec 05 2025?